Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
20 hedge funds and large institutions have $137M invested in Achilles Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 13 closing their positions.
25% less capital invested
Capital invested by funds: $184M → $137M (-$46.8M)
31% less funds holding
Funds holding: 29 → 20 (-9)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.29M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$132K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$116K |
| 4 |
Axa
Paris,
France
|
+$67.9K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.6M |
| 2 |
DM
Deerfield Management
New York
|
-$2.95M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$2.21M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.58M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$794K |
ACHL Hedge Fund Activity: Q3 2021 in Review
20 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2021, worth a combined $137M — down 25% from $184M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ACHL and 4 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.29M. The largest seller was Farallon Capital Management, cutting an estimated $3.6M.
- 20 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2021, down from 29 in Q2 2021.
- Funds reported $137M of Achilles Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
- 4 funds opened new Achilles Therapeutics positions in Q3 2021 and 13 closed out, a net change of -9 holders.
- The largest Achilles Therapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $3.29M added.
- The largest Achilles Therapeutics seller in Q3 2021 was Farallon Capital Management, an estimated $3.6M sold.
Based on aggregated 13F filings for Q3 2021.